Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	USD 4.970	-5.69%	249,514
03/09/26	USD 5.270	-5.22%	305,015
02/09/26	USD 5.560	-5.28%	225,380
01/09/26	USD 5.870	-18.19%	353,928
31/08/26	USD 7.175	+1.49%	190,250

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.970USD

Average target price

20.00USD

Spread / Average Target

+302.41%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 06:00:00 05/09/26 am AEST			5-day change	1st Jan Change
4.970 ^USD	-5.69%		-29.70%	-

18/08	Conexeu Sciences Advances CXU Platform And Completes 12-Month P.R.O.O.F. Phase Of Preclinical Program	CI
14/07	Conexeu Sciences Details Completion Of 12-Month P.R.O.O.F. Preclinical Study For CXU Platform	CI

Market Cap	133M 114M 108M 98.36M 184M 12.56B 184M 1.27B 494M 6.44B 499M 488M 20.75B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	133M 114M 108M 98.36M 184M 12.56B 184M 1.27B 494M 6.44B 499M 488M 20.75B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	53.71%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	CNXU	Delayed
CBOE	CNXU	Real-time

18/08	Conexeu Sciences Advances CXU Platform And Completes 12-Month P.R.O.O.F. Phase Of Preclinical Program	CI
14/07	Conexeu Sciences Details Completion Of 12-Month P.R.O.O.F. Preclinical Study For CXU Platform	CI
08/07	Conexeu Sciences Completes 12-Month Preclinical P.R.O.O.F Study for Cxu Platform and Announces Planned Move into Medical Aesthetics Market	CI
26/06	Conexeu Sciences Opens New Research and Development Facility At Admare M4 Innovation Centre in Vancouver	CI
25/06	Alert tagged to multiple companies from a research report withdrawn	RE
22/06	HC Wainwright Initiates Conexeu Sciences at Buy With $20 Price Target	MT
16/06	Conexeu Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
15/06	Conexeu Sciences Inc. Announces Management and Committee Changes, Effective June 15, 2026	CI
09/06	Conexeu Sciences Inc. Reports Manufacturing Scale Up And Regulatory Progress For Lead CXU Wound Care Program	CI
29/05	Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T. Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine	CI
22/05	Conexeu Sciences Inc.(NasdaqCM:CNXU) added to NASDAQ Composite Index	CI
19/05	Conexeu Sciences Inc. Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants	CI
14/05	Conexeu Sciences Inc Unveils Architecting Bioregeneration and Announces CXU Device Candidate	CI

Conexeu Sciences Inc. Stock

Stocks

CNXU

US20715F1003

Biotechnology & Medical Research

Valuation : Conexeu Sciences Inc.

Chart: Conexeu Sciences Inc.

Latest news : Conexeu Sciences Inc.

Analysts' recommendations : Conexeu Sciences Inc.

Press Releases : Conexeu Sciences Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Conexeu Sciences Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

01/09	Conexeu Sciences Sets September and October 2026 Conference Schedule	AQ
19/08	A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.	AQ
18/08	The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too.	AQ
18/08	Conexeu Sciences : Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration	PU
12/08	The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For	AQ

1 day	-5.69%
1 week	-29.70%
Current month	-30.73%
1 month	-41.32%
3 months	-67.40%

1 week	4.85	7.25
1 month	4.85	10.46
Current year	4.85	18.79
1 year	4.85	18.79
3 years	4.85	18.79
5 years	4.85	18.79
10 years	4.85	18.79

Manager	Title	Age	Since
Miles Harrison CEO	Chief Executive Officer	61	23/10/2025
Claudia Chavez-Munoz CTO	Chief Tech/Sci/R&D Officer	46	16/10/2023
David Bogart PRN	Corporate Officer/Principal	56	15/06/2026

Director	Title	Age	Since
David Bogart BRD	Director/Board Member	56	13/11/2023
Jeffrey Nathan Sharpe CHM	Chairman	54	23/10/2025
Miles Harrison BRD	Director/Board Member	61	23/10/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
26/5/26	Michael Wright	Exercice		800,000	-	-
22/5/26	Jeffrey Nathan Sharpe	Exercice	Chairman	1,000,000	-
14/5/26	Z. Paul Lorenc	Free	Director	11,175	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONEXEU SCIENCES INC.	-5.69%	-29.70%	-	-	133M
LONZA GROUP AG	-0.90%	-2.60%	-1.51%	+14.05%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+527.30%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+22.37%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+77.49%	40.73B
CELLTRION, INC.	+0.53%	-1.36%	+16.87%	+46.82%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+120.75%	16.5B
EUROFINS SCIENTIFIC SE	-1.46%	-1.21%	+12.11%	+31.25%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.12%	13.77B
Average	-1.28%	-2.49%	+73.86%	+110.14%	27.51B
Weighted average by Cap.	-0.77%	+0.10%	+89.37%	+128.89%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-